Neuroprotective effect of peptides extracted from walnut (Juglans Sigilata Dode) proteins on Aβ25-35-induced memory impairment in mice

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 36, Issue 1, 2016, Pages 21-30

  Zou, Juan ^a   Cai, Pei shan ^a   Xiong, Chao mei ^a   Ruan, Jin lan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Alzheimer s disease; A 25 35; neuroinflammation; oxidative stress; walnut peptides

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (25-35); GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN DERIVATIVE; MALONALDEHYDE; NEUROPROTECTIVE AGENT; NITRIC OXIDE; PEPTIDE; PEPTIDE FRAGMENT; PLANT EXTRACT; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; DRUG EFFECTS; FEMALE; HIPPOCAMPUS; MALE; MAZE TEST; MEMORY DISORDERS; METABOLISM; MOUSE; WALNUT;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; FEMALE; GLUTATHIONE; HIPPOCAMPUS; INTERLEUKINS; JUGLANS; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY DISORDERS; MICE; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NITRIC OXIDE; PEPTIDE FRAGMENTS; PEPTIDES; PLANT EXTRACTS; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957083963     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-016-1536-4     Document Type: Article

References (70)

1. Alagiakrishnan K, GillS S, Fagarasanu A. Genetics and epigenetics of Alzheimer’s disease. Postgrad Med J, 2012,88(1043):522–529
2. Durazzo TC, Mattsson N, Weiner MW. Smoking and increased Alzheimer’s disease risk: A review of potential mechanisms. Alzheimer’s Dement, 2014,10(3):S122–S145
3. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: A systematic review and meta analysis. Alzheimer’s Dement, 2013,9(1):63–75
4. Tang BL. Neuronal protein trafficking associated with Alzheimer disease. Cell Adhes Migr, 2009,3(1):118–128
5. Corporation HP. Protein Tau: prime cause of synaptic and neuronal degeneration in Alzheimer’s disease. Int J Alzheimer’s Dement, 2012,2012:1–13
6. Cai Z, Zhao B, Ratka A. Oxidative streβs and β-amyloid protein in Alzheimer’s disease. Neuro Mol Med, 2011,13(4):223–250
7. Zhang J, Zhen YF, Pu-Bu-Ci-Ren, et al. Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus. Behav Brain Res, 2013,244(3):70–81
8. Pérez-Severiano F, Salvatierra-Sánchez R, Rodríguez-Pérez M, et al. S-Allylcysteine prevents amyloid-β peptide-induced oxidative stress in rat hippocampus and ameliorates learning deficits. Eur J Pharmacol, 2004,489(3):197–202
9. Galoyan AA, Sarkiβsian JS, Chavushyan VA, et al. Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25–35 model of Alzheimer’s disease. Alzheimer’s Dement, 2008,4(5):332–344
10. Yamaguchi Y, Kawashima S. Effects of amyloid-β-(25–35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacology, 2001,412(3):265–272
11. Selkoe DJ. Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J AD, 2001,3(1):75–80
12. Mhatre M., Floyd RA, Hensley K. Oxidative stress and neuroinflammation in Alzheimer’s disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J AD, 2004,6(2):147–157
13. Broussard GJ, Mytar J, Li RC, et al. The role of inflammatory processes in Alzheimer’s disease. Inflammopharmacology, 2012,20(3):109–126
14. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacotherapy, 2004,58(1):39–46
15. De Iuliis A, Grigoletto J, Recchia A, et al. A proteomic approach in the study of an animal model of Parkinson’s disease. Clin Chim Acta, 2005,357(2):202–209
16. Qin L, Liu Y, Wang T, et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem, 2003,279(2):1415–1421
17. Lee IT, Yang CM. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochem Pharmacol, 2012,84 (5):581–590
18. Hsieh HL, Yang CM. Role of redox signaling in neuroinflammation and neurodegenerative diseases. BioM Res Int, 2013,2013(4):1–18
19. Moore AH, O’Banion MK. Neuroinflammation and anti-Inflammatory therapy for Alzheimer’s Disease. Adv Drug Delivery Rev, 2002,54(12):1627–1656
20. Erickson MA, Hansen K, Banks WA. Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood–brain barrier: Protection by the antioxidant N-acetylcysteine. Brain Behav Immun, 2012,26(7):1085–1094
21. Martínez ML, Labuckas DO, Lamarque AL, et al. Walnut (Juglans regia L.): genetic resources, chemistry, by-products. J Sci Food Agri, 2010,90(12):1393–1401
22. Kar Wai Clara Sze-Tao, Shridhar KS. Walnuts (Juglans regia L): proximate composition, protein solubility, protein amino acid composition and protein in vitro digestibility. J Sci Food Agri, 2000,80(9):1393–1401
23. Poulose SM, Miller MG, Shukitt-Hale B. Role of walnuts in maintaining brain health with age. J Nutr, 2014,144(4):561S-566S
24. Muthaiyah B, Essa MM, Lee M, et al. Dietary Supplementation of walnuts improves memory deficits and learning skills in transgenic mouse model of Alzheimer’s disease. J AD, 2014,42(4):1397–1405
25. Willis LM, Shukitt-Hale B, Joseph JA. Modulation of cognition and behavior in aged animals: role for antioxidant-and essential fatty acid-rich plant foods. Am J Clin Nutr, 2009,89(5):1602S-1606S
26. Pribis P, Bailey RN, Russell AA, et al. Effects of walnut consumption on cognitive performance in young adults. Brit J Nutr, 2011,107(09):1393–1401
27. Willis LM, Shukitt-Hale B, Cheng V, et al. Dose-dependent effects of walnuts on motor and cognitive function in aged rats. Brit J Nutr, 2009,101(8):1140–1144
28. Gu M, Chen H P, Zhao MM, et al. Identification of antioxidant peptides released from defatted walnut (Juglans Sigillata Dode) meal proteins with pancreatin. LWT-Food Sci Technol, 2015,60(60):213–220
29. Lee YW, Kim DH, Jeon SJ, et al. Neuroprotective effects of salvianolic acid B on an Aβ25–35 peptide-induced mouse model of Alzheimer’s disease. Eur J Pharmacol, 2013,704:70–77
30. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth, 1984,11(1):47–60
31. Wei H, Wu G, Chen J, et al. (2S)-5, 2', 5'-Trihydroxy-7-methoxyflavanone, a natural product from Abacopteris penangiana, presents neuroprotective effects in vitro and in vivo. Neurochem Res, 2013,38(8):1686–1694
32. Liu Z, Zhao X, Liu B, et al. Jujuboside A, a neuroprotective agent from semen Ziziphi Spinosae ameliorates behavioral disorders of the dementia mouse model induced by Aβ1–42. Eur J Pharmacol, 2014,738:206–213
33. Fu W, Lei Y, Chen J, et al. Parathelypteriside attenuates cognition deficits in d-galactose treated mice by increasing antioxidant capacity and improving long-term potentiation. Neurobio Learn Mem, 2010,94(3):414–421
34. Rubio J, Dang H, Gong M, et al. Aqueous and hydroalcoholic extracts of Black Maca (Lepidium meyenii) improve scopolamine-induced memory impairment in mice. Food Chem Toxicol, 2007,45(10):1882–1890
35. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 1990,250(4978):279–282
36. Delobette S, Privat A, Maurice T. In vitro aggregation facilitates β-amyloid peptide-(25-35)-inducedamnesia in the rat. Eur J Pharmacol, 1997,319(1):1–4
37. Gulyaeva NV, Victorov IV, Stepanichev MY, et al. Intracerebroventricular administration of beta-amyloid peptide (25-35) induces oxidative stress and neurodegeneration in rat brain. Adv Behav Biol, 1998,49:89–98
38. Oliveira MG M, BuenoOF A, PomaricoAC, et al. Strategies used by hippocampal-and caudate-putamen-lesioned rats in a learning task. Neurobiol Learn Mem, 1997,68 (1):32–41
39. Sultana R, Butterifield DA. Role of oxidative stress in the progression of Alzheimer’s Disease. JAD, 2010,19(Suppl 2):341–353
40. Tayler H, Fraser T, Miners JS, et al. Oxidative balance in Alzheimer’s Disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β. JAD, 2010,22(4):1363–1373
41. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid β-peptideassociated free radical oxidative stress. Free Radical Bio-Med, 2002, 32:1050–1060
42. Gardner AM, Xu FH, Fady C, et al. Apoptotic vs. nonapoptotic cytotoxicity induced by hydrogen peroxide. Free Radical BioMed, 1997,22 (1–2):73–83
43. Fiers W, Beyaert R, Declercq W, et al. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene, 1999,18(54):7719–7730
44. Miller DB, O’Callaghan JP. Aging, stress and the hippocampus. Ageing Res Rev, 2005,4(2):123–140
45. Yargicoglu P, Sahin E, Gümüslü S, et al. The effect of sulfur dioxide inhalation on active avoidance learning, antioxidant status and lipid peroxidation during aging. Neurotoxicol Teratol, 2007,29(2):211–218
46. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease brain. Brain Res, 2004,1000(1–2):1–7
47. Zampagni M, Wright D, Cascella R, et al. Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models. Free Radical BioMed, 2012,52(8):1362–1371
48. Mecocci P, MacGarvey U, Kaufman AE, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol, 1993, 34(4):609–616
49. Mamelak M. Alzheimer’ s disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging, 2007,28(9): 1340–1360
50. Rall L C, Roubenoff R, Meydani SN, et al. Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: effect of progressive resistance training. J Nutr Biochem, 2000,11(11–12):581–584 (4)
51. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Retour Au Numéro, 2009,73(14):768–774
52. Zhu H, Jia Z, Misra H, et al. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: Updated experimental and clinical evidence. J Digest Dis, 2012,13(3):133–142
53. Heneka M, Obanion M. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol, 2007,184(1):69–91
54. Xia W, Li D W, Xiang L, et al. Neuroprotective effects of an aqueous extract of futokadsura stem in an Aβ-induced Alzheimer’s disease-like rat model. Chinese J Physiol, 2015,58(2):104–113
55. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Therapeut, 2010,128(3):519–548
56. Heyser CJ, Masliah E, Samimi A, et al. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. P Natl Acad Sci, 1997,94(4):1500–1505
57. Huell M, Strauss S, Volk B, et al. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer’s disease patients. Acta Neuropathol, 1995,89(6):544–551
58. Liu L, Chan C. The role of inflammasome in Alzheimer’s disease. Ageing Res Rev, 2014,15:6–15
59. García-Ayllón MS, Silveyra MX, Sáez-Valero J. Aβsociation between acetylcholinesterase and β-amyloid peptide in Alzheimer’s cerebrospinal fluid. Chem-Biol Interact, 2008,175(1–3):209–215
60. Melo JB, Agostinho P, Oliveira CR. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci Res, 2003,45(1):117–127
61. Diaz A, Mendieta L, Zenteno E, et al. The role of NOS in the impairment of spatial memory and damaged neurons in rats injected with amyloid beta 25–35 into the temporal cortex. Pharmacol Biochem Be, 2011,98(1):67–75
62. Law A, Gauthier S, Quirion R. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer’s type. Brain Res Rev, 2001,35 (1):73–96
63. Singleton AB, Gibson AM, Mckeith IG, et al. Nitric oxide synthase gene polymorphisms in Alzheimer’s disease and dementia with Lewy bodies. Neurosci Lett, 2001,303(1): 33–36
64. Guo LY, Hung TM, Bae KH, et al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. EurJ Pharmacol, 2008,591(1–3):293–299
65. Yuan Q, Zhang X, Liu Z, et al. Ethanol extract of Adiantum capillus-veneris L. suppresses the production of inflammatory mediators by inhibiting NF-κB activation. J Ethnopharmacol, 2013,147(3):603–611
66. Wang H, Wu T, Qi J, et al. Salidroside attenuates LPS-stimulated activation of THP-1 cell-derived macrolhages through down-regulation of MAPK/NF-kB signaling pathways. J Huazhong Univ Sci Technol [Med Sci], 2013,33(4):463–469
67. Zhang ZH, Yu LJ, Hui XC, et al. Hydroxy-safflor Yellow A attenuates Aβ1–42-induced inflammation by modulating the JAK2/STAT3/NF-κB pathway. Brain Res, 2014:72–80
68. Wang C, Li J, Liu Q, et al. Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF-κB activation in a rat model of amyloid-beta-induced Alzheimer’s disease. Neurosci Lett, 2011,491(2):127–132
69. Luo Y, Yang Y P, Liu J, et al. Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res, 2014,1565(20):37–47
70. Lee SY, Lee JW, Lee H, et al. Inhibitory effect of green tea extract on β-amyloid-induced PC12 cell death by inhibition of the activation of NF-κB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Mol Brain Res, 2005,140(1–2):45–54